Frontiers in Immunology (May 2024)
The role of donor hypertension and angiotensin II in the occurrence of early pancreas allograft thrombosis
- Christophe Masset,
- Christophe Masset,
- Julien Branchereau,
- Julien Branchereau,
- Fanny Buron,
- Georges Karam,
- Georges Karam,
- Maud Rabeyrin,
- Karine Renaudin,
- Karine Renaudin,
- Florent Le Borgne,
- Lionel Badet,
- Xavier Matillon,
- Christophe Legendre,
- Denis Glotz,
- Corinne Antoine,
- Magali Giral,
- Magali Giral,
- Jacques Dantal,
- Jacques Dantal,
- Diego Cantarovich,
- Diego Cantarovich,
- DIVAT Consortium,
- Lionel Badet,
- Maria Brunet,
- Fanny Buron,
- Rémi Cahen,
- Ricardo Codas,
- Sameh Daoud,
- Valérie Dubois,
- Coralie Fournie,
- Arnaud Grégoire,
- Alice Koenig,
- Charlène Lévi,
- Emmanuel Morelon,
- Claire Pouteil-Noble,
- Maud Rabeyrin,
- Thomas Rimmelé,
- Olivier Thaunat,
- Gilles Blancho,
- Julien Branchereau,
- Diego Cantarovich,
- Agnès Chapelet,
- Jacques Dantal,
- Clément Deltombe,
- Lucile Figueres,
- Raphael Gaisne,
- Claire Garandeau,
- Magali Giral,
- Caroline Gourraud-Vercel,
- Maryvonne Hourmant,
- Georges Karam,
- Clarisse Kerleau,
- Delphine Kervella,
- Christophe Masset,
- Aurélie Meurette,
- Simon Ville,
- Christine Kandell,
- Anne Moreau,
- Karine Renaudin,
- Florent Delbos,
- Alexandre Walencik,
- Anne Devis,
- Lucile Amrouche,
- Dany Anglicheau,
- Olivier Aubert,
- Lynda Bererhi,
- Christophe Legendre,
- Alexandre Loupy,
- Frank Martinez,
- Arnaud Méjean,
- Rébecca Sberro-Soussan,
- Anne Scemla,
- Marc-Olivier Timsit,
- Julien Zuber,
- Gillian Divard,
- Carmen Lefaucheur,
- Denis Glotz
Affiliations
- Christophe Masset
- Institut de Transplantation-Urologie-Néphrologie (ITUN), Nantes University Hospital, Nantes, France
- Christophe Masset
- Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France
- Julien Branchereau
- Institut de Transplantation-Urologie-Néphrologie (ITUN), Nantes University Hospital, Nantes, France
- Julien Branchereau
- Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France
- Fanny Buron
- Groupement Hospitalier Edouard Herriot Service d’urologie chirurgie de la transplantation, Lyon, France
- Georges Karam
- Institut de Transplantation-Urologie-Néphrologie (ITUN), Nantes University Hospital, Nantes, France
- Georges Karam
- Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France
- Maud Rabeyrin
- Groupement Hospitalier Edouard Herriot, Service d’anatomie et pathologie, Lyon, France
- Karine Renaudin
- Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France
- Karine Renaudin
- Service d’anatomie et pathologie, CHU de Nantes, Nantes, France
- Florent Le Borgne
- INSERM UMR 1246 - SPHERE, Nantes University, Nantes, France
- Lionel Badet
- Groupement Hospitalier Edouard Herriot Service d’urologie chirurgie de la transplantation, Lyon, France
- Xavier Matillon
- Groupement Hospitalier Edouard Herriot Service d’urologie chirurgie de la transplantation, Lyon, France
- Christophe Legendre
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
- Denis Glotz
- Institut de Recherche Saint Louis, INSERM U976, Paris, France
- Corinne Antoine
- Institut de Recherche Saint Louis, INSERM U976, Paris, France
- Magali Giral
- Institut de Transplantation-Urologie-Néphrologie (ITUN), Nantes University Hospital, Nantes, France
- Magali Giral
- Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France
- Jacques Dantal
- Institut de Transplantation-Urologie-Néphrologie (ITUN), Nantes University Hospital, Nantes, France
- Jacques Dantal
- Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France
- Diego Cantarovich
- Institut de Transplantation-Urologie-Néphrologie (ITUN), Nantes University Hospital, Nantes, France
- Diego Cantarovich
- Nantes Université, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, Nantes, France
- DIVAT Consortium
- Lionel Badet
- Maria Brunet
- Fanny Buron
- Rémi Cahen
- Ricardo Codas
- Sameh Daoud
- Valérie Dubois
- Coralie Fournie
- Arnaud Grégoire
- Alice Koenig
- Charlène Lévi
- Emmanuel Morelon
- Claire Pouteil-Noble
- Maud Rabeyrin
- Thomas Rimmelé
- Olivier Thaunat
- Gilles Blancho
- Julien Branchereau
- Diego Cantarovich
- Agnès Chapelet
- Jacques Dantal
- Clément Deltombe
- Lucile Figueres
- Raphael Gaisne
- Claire Garandeau
- Magali Giral
- Caroline Gourraud-Vercel
- Maryvonne Hourmant
- Georges Karam
- Clarisse Kerleau
- Delphine Kervella
- Christophe Masset
- Aurélie Meurette
- Simon Ville
- Christine Kandell
- Anne Moreau
- Karine Renaudin
- Florent Delbos
- Alexandre Walencik
- Anne Devis
- Lucile Amrouche
- Dany Anglicheau
- Olivier Aubert
- Lynda Bererhi
- Christophe Legendre
- Alexandre Loupy
- Frank Martinez
- Arnaud Méjean
- Rébecca Sberro-Soussan
- Anne Scemla
- Marc-Olivier Timsit
- Julien Zuber
- Gillian Divard
- Carmen Lefaucheur
- Denis Glotz
- DOI
- https://doi.org/10.3389/fimmu.2024.1359381
- Journal volume & issue
-
Vol. 15
Abstract
BackgroundAbout 10–20% of pancreas allografts are still lost in the early postoperative period despite the identification of numerous detrimental risk factors that correlate with graft thrombosis.MethodsWe conducted a multicenter study including 899 pancreas transplant recipients between 2000 and 2018. Early pancreas failure due to complete thrombosis, long-term pancreas, kidney and patient survivals were analyzed and adjusted to donor, recipient and perioperative variables using a multivariate cause-specific Cox model stratified to transplant centers.ResultsPancreas from donors with history of hypertension (6.7%), as well as with high body mass index (BMI), were independently associated with an increased risk of pancreas failure within the first 30 post-operative days (respectively, HR= 2.57, 95% CI from 1.35 to 4.89 and HR= 1.11, 95% CI from 1.04 to 1.19). Interaction term between hypertension and BMI was negative. Donor hypertension also impacted long-term pancreas survival (HR= 1.88, 95% CI from 1.13 to 3.12). However, when pancreas survival was calculated after the postoperative day 30, donor hypertension was no longer a significant risk factor (HR= 1.22, 95% CI from 0.47 to 3.15). A lower pancreas survival was observed in patients receiving a pancreas from a hypertensive donor without RAAS (Renin Angiotensin Aldosterone System) blockers compared to others (50% vs 14%, p < 0.001). Pancreas survival was similar among non-hypertensive donors and hypertensive ones under RAAS blockers.ConclusionDonor hypertension was a significant and independent risk factor of pancreas failure. The well-known pathogenic role of renin-angiotensin-aldosterone system seems to be involved in the genesis of this immediate graft failure.
Keywords
- body mass index (BMI)
- pre-procurement pancreas suitability score
- pancreas transplantation
- allograft thrombosis
- high blood pressure
- immunothrombosis